Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26662783 | 1.00 | PDPK1 (0.33) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL25351955 | 0.93 | SSTR4 (0.32) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL2386488 | 0.89 | SSTR4 (0.34) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL29837499 | 0.87 | MAPKAPK2 (0.36) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL16926331 | 0.87 | MAPKAPK2 (0.36) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL29726264 | 0.85 | PDPK1 (0.34) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL16848701 | 0.85 | PDPK1 (0.34) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL20839302 | 0.84 | PDPK1 (0.35) | PDPK1SSTR4USP30 | |
| SCHEMBL22958315 | 0.82 | PDPK1 (0.34) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL29726252 | 0.82 | PDPK1 (0.34) | PDPK1SSTR4USP30BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4225737-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076628-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PDPK1 1644/4885SSTR4 3138/4885USP30 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.